FC
ABBV icon

Fusion Capital’s AbbVie ABBV Stock Holding History

Fusion Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$690K Sell
3,172
-16
-0.5% -$3.55K 0.19% 50
2025
Q4 		$728K Buy
3,188
+18
+0.6% +$4.1K 0.2% 47
2025
Q3 		$691K Buy
3,170
+76
+2% +$15.5K 0.2% 48
2025
Q2 		$574K Sell
3,094
-10
-0.3% -$1.86K 0.2% 50
2025
Q1 		$650K Sell
3,104
-273
-8% -$53.1K 0.25% 45
2024
Q4 		$600K Buy
3,377
+23
+0.7% +$4.23K 0.24% 51
2024
Q3 		$662K Buy
3,354
+21
+0.6% +$3.92K 0.28% 42
2024
Q2 		$572K Sell
3,333
-90
-3% -$14.9K 0.26% 42
2024
Q1 		$623K Sell
3,423
-36
-1% -$6.2K 0.29% 41
2023
Q4 		$536K Sell
3,459
-274
-7% -$39.9K 0.27% 38
2023
Q3 		$556K Sell
3,733
-102
-3% -$15K 0.31% 36
2023
Q2 		$517K Buy
3,835
+85
+2% +$12.5K 0.29% 37
2023
Q1 		$598K Buy
3,750
+31
+0.8% +$4.74K 0.34% 33
2022
Q4 		$601K Buy
3,719
+154
+4% +$23.6K 0.35% 35
2022
Q3 		$479K Sell
3,565
-49
-1% -$7.03K 0.31% 37
2022
Q2 		$554K Sell
3,614
-12
-0.3% -$1.83K 0.34% 36
2022
Q1 		$588K Buy
3,626
+34
+0.9% +$4.94K 0.31% 39
2021
Q4 		$486K Buy
3,592
+200
+6% +$23.6K 0.25% 46
2021
Q3 		$366K Buy
3,392
+215
+7% +$24.6K 0.22% 54
2021
Q2 		$358K Buy
3,177
+96
+3% +$10.8K 0.22% 53
2021
Q1 		$333K Buy
3,081
+113
+4% +$12.1K 0.22% 53
2020
Q4 		$318K Buy
2,968
+138
+5% +$13.3K 0.23% 52
2020
Q3 		$248K Buy
2,830
+81
+3% +$7.63K 0.22% 55
2020
Q2 		$270K Buy
+2,749
New +$242K 0.26% 48

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fusion Capital's ABBV Position: Q1 2026 in Review

Fusion Capital reduced its AbbVie (ABBV) stake by 0.5% in Q1 2026, selling an estimated $3.55K and leaving 3,172 shares worth $690K. The position accounts for 0.19% of the portfolio, ranked #50.

Fusion Capital first reported a position in ABBV in Q2 2020 and has held it in 24 quarters since. The position peaked at $728K in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Fusion Capital held 3,172 shares of AbbVie worth $690K as of Q1 2026.
  • Fusion Capital sold 16 AbbVie shares in Q1 2026, an estimated $3.55K.
  • AbbVie made up 0.19% of Fusion Capital's portfolio in Q1 2026, its #50 holding.
  • Fusion Capital first reported a position in AbbVie in Q2 2020 and has held it in 24 quarters since.
  • Fusion Capital's AbbVie position peaked at $728K in Q4 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fusion Capital's 13F filing for Q1 2026, filed 13 May 2026.